Latest On Sumitomo Dainippon Pharma Co., Ltd (DNPUF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-10-25 05:51 EST | News | Myovant Sciences cancels Q2 earnings call in light of Sumitovant acquisition | N/A |  |
| 2022-10-24 16:06 EST | News | Myovant stock pops as Sumitovant to acquire remaining stake for $1.7B | N/A | |
| 2021-07-22 13:45 EST | News | Nabriva antibiotic meets primary endpoint in phase 3 trial; shares soar 40% | N/A | |
| 2021-03-30 06:09 EST | Dividend | A dividend of $14 has been announced on May 13, 2020. It will be paid Nov 30, -0001 with an ex-dividend date of Mar 30, 2021. | Neutral | |
| 2021-01-29 13:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-26 23:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 02:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 18:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-02 09:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 15:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 07:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 11:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 15:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-02 10:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 19:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 07:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 23:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 15:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 19:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 11:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 02:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 06:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 08:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 07:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-24 10:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 03:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-17 02:10 EST | News | Stocks To Watch: Retail Heavyweights, Nvidia, Bristol-Myers And 5G Plays | N/A | |
| 2020-05-06 07:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 18:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-20 06:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-09 22:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-09 10:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-03 23:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-30 06:13 EST | Dividend | A dividend of $14 has been announced on May 10, 2019. It will be paid Jan 1, 1970 with an ex-dividend date of Mar 30, 2020. | Neutral | |
| 2020-03-25 22:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 06:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 00:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-22 01:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-21 01:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-18 01:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-13 01:47 EST | Financials | Company financials have been released. | Neutral | |
About Sumitomo Dainippon Pharma Co., Ltd (DNPUF):
Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio, Inc. It also has a strategic research collaboration agreement with Gain Therapeutics, Inc. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
General
- Name Sumitomo Dainippon Pharma Co., Ltd
- Symbol DNPUF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 6,457
- Fiscal Year EndMarch
- Web URLhttp://www.ds-pharma.com
Valuation
- Trailing PE 11.5
- Forward PE 15.2
- Price/Sales (Trailing 12 Mt.) 1.37
- Price/Book (Most Recent Quarter) 1.31
- Enterprise Value Revenue 0.02
- Enterprise Value EBITDA 0.07
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 13%
- Return on Assets 5%
- Return on Equity 9%
- Revenue Per Share $0
- Gross Profit 353.06 billion
- Quarterly Earnings Growth 5.4%
ESG Rating
Highlights
- Market Capitalization 7.54 billion
Share Statistics
- Shares Outstanding 397.3 million
- Shares Float 173.82 million
- % Held by Insiders 5925%
- % Held by Institutions 18.59%
Technicals
- Beta 0.39
- 52 Week High $16.5
- 52 Week Low $12.15
- 50 Day Moving Average 15.83
- 200 Day Moving Average 14.07
Dividends
- Forward Annual Dividend Rate $0.26
- Forward Annual Dividend Yield 1.58%
- Payout Ratio 16%
- Dividend Date N/A
- ExDividend Date 2021-03-30
- Dividend Per Share $0.26
- Dividend Yield 0%
Sumitomo Dainippon Pharma Co., Ltd (DNPUF) Dividend Calendar:
Sumitomo Dainippon Pharma Co., Ltd pays out 16% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Sumitomo Dainippon Pharma Co., Ltd (DNPUF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $N/A | $0.79 | ||
| 2020-09-30 | 2020-12-31 | $N/A | $0.80 | $17.15 | -95.32% |
| 2020-06-30 | 2020-09-30 | $N/A | $0.45 | $19.66 | -97.69% |
| 2020-03-31 | 2020-06-30 | $N/A | $0.43 | $31.92 | -98.67% |
| 2019-12-31 | 2020-03-31 | $126.41 billion | -$0.08 | $20.58 | -100.37% |
| 2019-09-30 | 2019-12-31 | $113.12 billion | $0.32 | $9.24 | -96.58% |
| 2019-06-30 | 2019-09-30 | $117.48 billion | $0.55 | $28.20 | -98.05% |
| 2019-03-31 | 2019-06-30 | $112.4 billion | $0.16 | $23.70 | -99.34% |
| 2018-12-31 | 2019-03-31 | $120.72 billion | $0.20 | $22.10 | -99.11% |
| 2018-09-30 | 2018-12-31 | $16.05 billion | $0.28 | $18.80 | -98.52% |
| 2018-06-30 | 2018-09-30 | $3.79 billion | $0.28 | $28.05 | -99% |
| 2018-03-31 | 2018-06-30 | $102.72 billion | $0.35 | $21.00 | -98.35% |
| 2017-12-31 | 2018-03-31 | $1.94 billion | $0.07 | $20.85 | -99.68% |
| 2017-09-30 | 2017-12-31 | $4.09 billion | $0.35 | ||
| 2017-06-30 | 2017-09-30 | $116.3 billion | $0.46 | $22.65 | -97.98% |
| 2017-03-31 | 2017-06-30 | $106.13 billion | $0.32 | $11.70 | -97.24% |
| 2016-12-31 | 2017-03-31 | -$0.01 | $19.40 | -100.07% | |
| 2016-09-30 | 2016-12-31 | $0.40 | $15.40 | -97.39% | |
| 2016-06-30 | 2016-09-30 | $0.06 | $13.40 | -99.53% | |
| 2016-03-31 | 2016-06-30 | $0.21 | $7.70 | -97.34% | |
| 2015-12-31 | 2016-03-31 | $0.03 | $9.70 | -99.69% | |
| 2015-09-30 | 2015-12-31 | $0.21 | $10.10 | -97.9% | |
| 2015-06-30 | 2015-09-30 | $0.15 | |||
| 2015-03-31 | 2015-06-30 | $0.12 | |||
| 2014-12-31 | 2015-03-31 | -$0.07 | $15.10 | -100.49% | |
| 2014-09-30 | 2014-12-31 | $0.15 | $21.80 | -99.3% | |
| 2014-06-30 | 2014-09-30 | $0.14 | |||
| 2014-03-31 | 2014-06-30 | $0.14 | |||
| 2013-12-31 | 2014-03-31 | $0.02 | |||
| 2013-09-30 | 2013-12-31 | $0.25 | |||
| 2013-06-30 | 2013-09-30 | $0.10 | |||
| 2013-03-31 | 2013-06-30 | $0.12 | |||
| 2012-12-31 | 2013-03-31 | -$0.18 | |||
| 2012-09-30 | 2012-12-31 | $0.17 | |||
| 2012-06-30 | 2012-09-30 | $0.17 | |||
| 2012-03-31 | 2012-06-30 | $0.18 | |||
| 2011-12-31 | 2012-03-31 | -$0.05 | |||
| 2011-09-30 | 2011-12-31 | $0.02 | |||
| 2011-06-30 | 2011-09-30 | $0.05 | |||
| 2011-03-31 | 2011-06-30 | $0.25 | |||
| 2010-12-31 | 2011-03-31 | $0.06 | |||
| 2010-09-30 | 2010-12-31 | $0.19 | |||
| 2010-06-30 | 2010-06-30 | $0.25 | |||
| 2010-03-31 | 2010-03-31 | -$0.01 | |||
| 2009-12-31 | 2009-12-31 | $0.24 |
Sumitomo Dainippon Pharma Co., Ltd (DNPUF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 23.55 billion |
| Income Before Tax | N/A | N/A | N/A | N/A | 20.28 billion |
| Selling General Administrative | N/A | N/A | N/A | N/A | 50.77 billion |
| Gross Profit | N/A | N/A | N/A | N/A | 89.36 billion |
| Ebit | N/A | N/A | N/A | N/A | 14.63 billion |
| Operating Income | N/A | N/A | N/A | N/A | 14.63 billion |
| Income Tax Expense | 8.5 billion | 6.9 billion | 6.41 billion | 7.59 billion | 6.63 billion |
| Total Revenue | N/A | N/A | N/A | N/A | 126.41 billion |
| Cost of Revenue | N/A | N/A | N/A | N/A | 37.06 billion |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 5.65 billion |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | 13.65 billion |
| Net Income Applicable to Common Shares | 32.96 billion | 19.04 billion | 18.26 billion | -3.23 billion | 13.65 billion |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | -110.19 billion | -868 million |
| Change to Liabilities | 92 million | -7.73 billion | 6.67 billion | 4.43 billion | 2.34 billion |
| Total Cash Flow from Investing Activities | -2.16 billion | 21.53 billion | -27.97 billion | -295.52 billion | -5.87 billion |
| Net Borrowings | -943 million | -1.94 billion | -8.04 billion | 258.29 billion | -740 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | 251.65 billion | -1.86 billion |
| Change to Operating Activities | 6.09 billion | 7.67 billion | 10.02 billion | 2.81 billion | -26.53 billion |
| Change in Cash | N/A | N/A | N/A | -35.32 billion | 15.71 billion |
| Total Cash from Operating Activities | 25.55 billion | 517 million | 9.36 billion | 5 billion | 23.53 billion |
| Depreciation | N/A | N/A | N/A | 4.33 billion | 4.32 billion |
| Other Cash Flow from Investing Activities | 20 million | 158 million | 6 million | -6 million | -6 million |
| Change to Inventory | N/A | N/A | N/A | -4.93 billion | -1.27 billion |
| Change to Account Receivables | N/A | N/A | N/A | -6.58 billion | 1.05 billion |
| Other Cash Flow from Financing Activities | 558 million | -1.9 billion | -1.35 billion | -1.09 billion | -1.04 billion |
| Change to Net Income | 2.82 billion | -17.92 billion | 6.32 billion | -8.71 billion | 20 billion |
| Capital Expenditures | N/A | N/A | N/A | 1.02 billion | 2.95 billion |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 592.8 billion |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 519.92 billion |
| Other Current Liabilities | 178.4 billion | 155.47 billion | N/A | N/A | 155.81 billion |
| Total Assets | N/A | N/A | N/A | N/A | 1.12 trillion |
| Common Stock | 22.4 billion | 22.4 billion | 22.4 billion | 22.4 billion | 22.4 billion |
| Other Current Assets | 7.86 billion | 11.89 billion | N/A | N/A | 15.71 billion |
| Retained Earnings | 516.24 billion | 488.85 billion | 470.03 billion | 457.33 billion | 460.28 billion |
| Other Liabilities | 142.54 billion | 96.54 billion | 98.13 billion | 99.26 billion | 77.98 billion |
| Other Assets | 50.41 billion | 35.94 billion | 33.1 billion | 31.28 billion | 38.91 billion |
| Cash | N/A | N/A | N/A | N/A | 129.35 billion |
| Total Current Liabilities | 263.17 billion | 365.48 billion | N/A | N/A | 489.09 billion |
| Other Stockholder Equity | -7.23 billion | 16.26 billion | 31.74 billion | 35.78 billion | 22.06 billion |
| Property, Plant & Equipment | 62.76 billion | 63.73 billion | 64.52 billion | 65.75 billion | 71.09 billion |
| Total Current Assets | 464.72 billion | 377.42 billion | N/A | N/A | 348.21 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 180.72 billion |
| Net Tangible Assets | -16.33 billion | -28.93 billion | -42.62 billion | -61.35 billion | 43.69 billion |
| Short Term Investments | N/A | N/A | N/A | N/A | 3.89 billion |
| Long Term Debt | N/A | N/A | N/A | N/A | 25.74 billion |
| Inventory | 82.91 billion | 81.82 billion | N/A | N/A | 73.3 billion |
| Accounts Payable | 54.81 billion | 53.05 billion | N/A | N/A | 55.52 billion |
Sumitomo Dainippon Pharma Co., Ltd (DNPUF) Chart:
Sumitomo Dainippon Pharma Co., Ltd (DNPUF) News:
Below you will find a list of latest news for Sumitomo Dainippon Pharma Co., Ltd (DNPUF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Sumitomo Dainippon Pharma Co., Ltd (DNPUF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Sumitomo Dainippon Pharma Co., Ltd (DNPUF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|